performed a phase II clinical trial at two centers to test whether etanercept, which is a soluble receptor that binds to both TNFα and TNFβ, could reduce TNFR1 levels, ameliorate GVHD occurrence and improve survival (38). This evidence concerns the gene TNF and graft versus host disease.